AstraZeneca Plc (AZN)

40.12
0.61 1.50
NYSE : Health Technology
Prev Close 40.73
Open 40.52
Day Low/High 40.06 / 40.59
52 Wk Low/High 35.30 / 43.30
Volume 3.71M
Avg Volume 3.31M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 104.84B
EPS 0.80
P/E Ratio 18.26
Div & Yield 1.37 (3.40%)
Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Stocks declined on Tuesday as wild weather stifled activity and led to low volume.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Wake Up Wall Street: Donald Trump to Address Congress

Wake Up Wall Street: Donald Trump to Address Congress

U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.

Global Financial News: Nikkei 225 Snaps Losing Streak

Global Financial News: Nikkei 225 Snaps Losing Streak

Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close

AstraZeneca Has Started a Turnaround

AstraZeneca Has Started a Turnaround

The old saying that volume precedes price could be playing out

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

Here is a round-up of the headlines from Europe.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices

Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.

AstraZeneca upgraded at Leerink

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca Reports Positive Lung Cancer Drug Trial Results

AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.

What to Watch This Week: Presidential Election, Mylan Earnings

What to Watch This Week: Presidential Election, Mylan Earnings

For the week of November 7, all eyes will be on Tuesday's presidential election.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer: AstraZeneca Is Reinventing Itself in Anti-Cancer

Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher

Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher

Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.

AstraZeneca Likely to Grind Lower

Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

Bret Jensen Reporting for Duty

Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...

2 Small-Cap Biotechs With Big Ambitions

2 Small-Cap Biotechs With Big Ambitions

Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

Relypsa's Still a Bargain Despite 67% Rally

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.